Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
33 hedge funds and large institutions have $71.8M invested in Avadel Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
17% more capital invested
Capital invested by funds: $61.2M → $71.8M (+$10.6M)
3% more funds holding
Funds holding: 32 → 33 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$3.87M |
| 2 |
CM
Castleark Management
Chicago,
Illinois
|
+$2.94M |
| 3 |
Millennium Management
New York
|
+$1.25M |
| 4 |
Bank of New York Mellon
New York
|
+$151K |
| 5 |
CCI
Columbus Circle Investors
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
-$3.65M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$931K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$656K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$392K |
| 5 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$132K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $17K | +$16K | +2,600 | +4,727% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $8K | -$1.38K | -225 | -16% |
|
28
Group One Trading
Chicago,
Illinois
| $4K | -$33.8K | -5,500 | -89% |
|
|
WC
29
Whitnell & Co
Oak Brook,
Illinois
| $3K | – | – | – |
|
30
Citigroup
New York
| $1K | -$387 | -63 | -27% |
|
31
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
JIC
32
Joel Isaacson & Co
New York
| $1K | +$1.29K | +210 | New |
|
|
CLM
33
ClearBridge LLC (Maryland)
Baltimore,
Maryland
| – | -$3.65M | -595,053 | Closed |
|
|
BI
34
BVF Inc
San Francisco,
California
| – | -$931K | -151,406 | Closed |
|
|
OAM
35
Oxford Asset Management
Oxford,
United Kingdom
| – | -$74K | -12,089 | Closed |
|
AVDL Hedge Fund Activity: Q3 2013 in Review
33 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2013, worth a combined $71.8M — up 17% from $61.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AVDL positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $3.87M. The largest seller was ClearBridge LLC (Maryland), exiting entirely with an estimated $3.65M sold.
- 33 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2013, up from 32 in Q2 2013.
- Funds reported $71.8M of Avadel Pharmaceuticals stock for Q3 2013, up 17% quarter-over-quarter.
- 4 funds opened new Avadel Pharmaceuticals positions in Q3 2013 and 3 closed out, a net change of +1 holder.
- The largest Avadel Pharmaceuticals buyer in Q3 2013 was Broadfin Capital, an estimated $3.87M added.
- The largest Avadel Pharmaceuticals seller in Q3 2013 was ClearBridge LLC (Maryland), an estimated $3.65M sold.
Based on aggregated 13F filings for Q3 2013.